SAN ANTONIO--(BUSINESS WIRE)--Azaya Therapeutics Inc., a clinical-stage oncology company developing more effective cancer treatments through its nanotechnology platform, announced an exclusive license ...
Cytori Therapeutics said today it plans to acquire the liposomal nanoparticle technology platform of Azaya Therapeutics for up to $170 million, in a deal designed to expand and complement the buyer’s ...
Cytori Therapeutics Inc. stock surged 7.9% to $1.78 per share in morning trade Thursday after the company said it had agreed to purchase assets from privately-held Azaya Therapeutics. Under the terms ...
A group of university researchers are working with a San Antonio pharmaceutical company to test out an investigational drug. Azaya Therapeutics Inc. has entered into a collaboration with the ...
> Azaya Therapeutics, which is developing oncology drugs using a nanotechnology platform, has formed Parexo Labs as a contract development and manufacturing organization (CDMO). Item > The U.K.'s ...
Azaya Therapeutics, Inc. announced that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product “ATI-1123,” a novel and improved ...
Azaya Therapeutics is conducting a study of a generic version of a popular drug used to treat ovarian cancer. The company hopes that drug will fill a gap in the market next year. Azaya’s drug is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback